Innovation Pharmaceuticals Inc (IPIX)

[Here Today]

For quick numbers on Brilacidin for Covid-19 only - $400 million Upfront payment with a 20% Gross Sales Royalty payment.


So if only $4 billion in annual gross sales, that would be an additional $800 million in revenue for IPIX each year until the pandemic passes. IPIX can then pursue all the other clinical trials for Brilacidin’s other potential uses and also truly begin Kevetrin’s human clinical trials. Just my opinion.